Propanc Biopharma, Inc. reported earnings results for the full year ended June 30, 2022. For the full year, the company reported net loss was USD 2.66 million compared to USD 2.03 million a year ago. Basic loss per share from continuing operations was USD 50.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0007 USD | 0.00% | -30.00% | -94.17% |
1st Jan change | Capi. | |
---|---|---|
-94.17% | 83.53K | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- PPCB Stock
- News Propanc Biopharma, Inc.
- Propanc Biopharma, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022